SCHEMBL3975236

SCHEMBL3975236

Cc1ccc2nc(-c3ccc(Br)cc3)nc(CCCCN)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 4/20 0.39
CYP1A2 P05177 3/20 0.39
CYP1A1 P04798 2/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
ADORA3 P0DMS8 2/20 0.38
PDE5A O76074 2/20 0.37
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HSP90AA1 P07900 1/20 0.36
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
AURKA O14965 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974636 0.85 ADORA3 (0.47) CYP1B1CYP1A2CYP1A1ADORA3PDE5A
SCHEMBL3974657 0.81 SLC2A1 (0.50) ALDH1A1KDRSYK
SCHEMBL3973242 0.74 PDE5A (0.50) CYP1B1CYP1A2CYP1A1TP53MAPT
SCHEMBL3973898 0.73 LMNA (0.45) CYP1B1CYP1A2CYP1A1TP53MAPT
SCHEMBL3978935 0.71 LATS1 (0.52) TP53MAPTADORA3PDE5AALDH1A1
SCHEMBL3975242 0.71 RAD52 (0.45) TP53MAPTPDE5AALDH1A1SYK
SCHEMBL3975234 0.71 ACP1 (0.60) TP53MAPTPDE5AALDH1A1ALOX15
SCHEMBL3978931 0.71 KCNH2 (0.42) CYP1B1CYP1A2CYP1A1TP53MAPT
SCHEMBL3973245 0.69 PDE5A (0.62) CYP1B1CYP1A2CYP1A1TP53MAPT
SCHEMBL5401628 0.69 MPO (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 CYP1B1 3139/4885CYP1A2 1472/4885CYP1A1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.